Several media have reported on the collaboration between IRB Barcelona and Amazon. In this regard, IRB Barcelona’s Structural Bioinformatics and Network Biology Laboratory, headed by ICREA researcher Patrick Aloy, is collaborating with the American giant in the development of a tool based on Chemical Checker technology. This new tool aims to rapidly process the large volume of articles on COVID-19 and extract results that could be relevant in the search for a treatment.
The Structural Bioinformatics and Network Biology Lab is also participating in the European project RiPCoN, devoted to the identification of the human proteins that the virus uses for its expansion. This project seeks to identify drugs (already on the market or in clinical trials) that can modulate the activity of the virus and halt its replication.
Via: Europa Press
Via: El Punt Avui
Vía: La Vanguardia
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).